Europe’s leading exchange for life sciences companies
Swiss financial institutions manage more than one-quarter of the world’s offshore assets and represent the backbone of Switzerland’s strong financial marketplace. As a result, companies listed on SIX Swiss Exchange achieve a high level of visibility within this financially potent investor community.
In Switzerland, the life sciences industry in particular has developed over the past years into an internationally recognised and strongly emphasized sectoral focal point:

1. In Europe, SIX Swiss Exchange has grown to become the most important securities exchange in terms of the total market capitalisation of listed life sciences companies: 42% of Europe’s life sciences market capitalisation is attributable to the SIX Swiss Exchange.
2. Collectively, these representatives of the industry account for roughly one-third of the overall market capitalisation of the Swiss equity market.
3. Listed companies in the life sciences field such as Novartis, Roche and Actelion engender an environment that exudes global charisma.
4. Differentiated sector-specific indicators such as the SXI LIFE SCIENCES® and SXI Bio+Medtech® indices, as well as the unusually broad analyst coverage of this particular sector, ensure transparency and outstanding visibility.
5. The SIX Swiss Exchange has seen the largest biotech IPOs in Europe in terms of money raised on the day of the IPO every year since 2004 and was the only regulated exchange who recently attracted European biotech crossborder-IPOs.

With a public offering of securities in Switzerland, and thanks to the tremendous placing power afforded by the Swiss-based investment banks, life science companies gain access to a sectorally experienced, highly competent and broadly international circle of investors.
Moreover, the location-specific advantages of Switzerland and favourable general conditions contribute to the attractiveness of an initial public offering on the SIX Swiss Exchange:

1. The Continental European marketplace with the most pronounced international orientation
2. A leading financial centre for equity-focused institutional investors
3. A strong private banking industry with a broad investor base
4. Multilingual and multicultural investors
5. Focus on life sciences and small- and mid-caps
6. Numerous banks with established in-house research departments
7. Active bond and derivatives markets
8. An attractive, market-oriented regulatory environment thanks to self-regulation
9. Acceptance of various accounting standards (US-GAAP, IFRS, Swiss GAAP ARR and additional internationally recognised standards)
10. Low foreign exchange risk (listing in various currencies is possible)

Further information on the topic of IPOs on the SIX Swiss Exchange can be accessed at: www.six-swiss-exchange.com/download/about/div_pub/swx_ipoguide_en.pdf

Should you have further questions with regard to a public offering of securities, the various stock market segments or any other exchange-related topic, please feel free to contact our Issuer & Investor Relations team.

SIX Swiss Exchange
Issuer & Investor Relations
Selnaustrasse 30, Postfach, CH-8021 Zürich
T +41(0)58 854 22 45   F +41(0)58 854 22 40
E-mail: ipo@six-swiss-exchange.com

www.six-swiss-exchange.com

back to top